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Abstract
The expression of immunoglobulin-based artificial re-
ceptors in normal T lymphocytes provides a means to
target lymphocytes to cell surface antigens indepen-
dently of major histocompatibility complex restriction.
Such artificial receptors have been previously shown to
confer antigen-specific tumoricidal properties in murine
T cells. We constructed a novel z chain fusion receptor
( )specific for prostate-specific membrane antigen PSMA
termed Pz-1. PSMA is a cell-surface glycoprotein ex-
pressed on prostate cancer cells and the neovascular
endothelium of multiple carcinomas. We show that pri-
mary T cells harvested from five of five patients with
different stages of prostate cancer and transduced with
the Pz-1 receptor readily lyse prostate cancer cells.
Having established a culture system using fibroblasts
that express PSMA, we next show that T cells express-
ing the Pz-1 receptor release cytokines in response to
cell-bound PSMA. Furthermore, we show that the cy-
tokine release is greatly augmented by B7.1-mediated
costimulation. Thus, our findings support the feasibility
of adoptive cell therapy by using genetically engineered
T cells in prostate cancer patients and suggest that
both CD4H and CD8H T lymphocyte functions can be
synergistically targeted against tumor cells.
Keywords: gene therapy, prostate cancer, immunotherapy, retroviral-mediated
gene transfer, costimulation.
Introduction
The infusion of T lymphocytes as a therapeutic modality
against cancer is based on the premise that tumor-reactive
lymphocytes can be expanded ex vivo and retain their
antitumoral functions upon reinfusion in vivo. While autolo-
gous adoptive cell therapies have shown some beneficial
[ ]effects in cancer patients with solid tumors 1 , they are
limited by several biological obstacles that include difficul-
ties in generating tumor–specific lymphocytes and the likely
occurrence of anergy and/or cell death facing the infused
[ ]lymphocytes 2,3 . In principle, these shortcomings could be
in part remedied by genetically programming the T cells to
[ ]recognize tumor cells 4 and to survive in a proapoptotic
[ ] ( )environment 5 . Artificial T-cell receptors TCR that incor-
porate the antigen–specific moiety of an immunoglobulin,
( )expressed as a single chain antibody scFv , provide a
means to target antigens independently of major histocom-
( )patibility complex MHC expression. Such receptors are
therefore expected to target T cells to tumor cells irrespec-
tive of the patient’s MHC haplotype and of MHC expression
by tumor cells. The targeted antigen must be a cell surface
antigen, ideally absent from normal tissues or at least less
accessible therein. To elicit T-cell functions, recognition of
antigen must be followed by an activation signal transduced
via the receptor’s cytoplasmic domain. Artificial TCRs that
include the activation domain of the CD3–associated z
chain have been shown to confer tumoricidal properties to
[ ]murine T cells 4 . However, their activity in cancer patient
lymphocytes has not yet been reported.
We have created an scFv-based z chain fusion receptor,
termed Pz-1, that is specific for prostate-specific membrane
( )antigen PSMA . PSMA is a cell-surface glycoprotein ex-
pressed on prostate epithelial cells whose expression is
[ ]increased in advanced prostate cancer 6–8 . PSMA is thus
an attractive target molecule for immunotherapy in patients
with advanced prostate cancer, for which there is no effec-
tive treatment. Moreover, PSMA is found in the neovascula-
ture of numerous solid tumors including renal cell, urothelial,
colon and breast carcinomas as well as melanoma and
([ ] )sarcoma 8 ; Chang et al., manuscript submitted , and thus
lymphocyte targeting to PSMA is potentially of broader use.
Taking advantage of highly efficient gene transfer in human
[ ]primary T cells 9 , we therefore examined the function of z
chain fusion receptors in T cells from prostate cancer pa-
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interferon; IL-2, interleukin-2; MHC, major histocompatibility complex.; NTP, trun-
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Figure 1. Pz -1 vector structure and expression in primary human T
( ) (cells. A Schematic diagram of the Pz -1 retroviral vector Gong et al.,
)manuscript in preparation . J591-scFv: PSMA-specific scFv derived
( ) [ ]from the monoclonal antibody mAb J591 8 ; CD8: CD8 hinge and
transmembrane domains; zeta: T-cell receptor z chain cytoplasmic
domain; LTR: long terminal repeat; hatched box: CD8 leader sequence;
( ) ( )arrows indicate start of transcription. B FACS Becton Dickinson & Co
analysis of transduced primary T cells. PBL harvested from cancer
[ ]patients were transduced as previously described 9 and stained 3 days
after retroviral infection to enumerate the fraction of Pz -1q CD4q and
Pz-1q CD8q lymphocytes. Lymphocytes were incubated with an
FITC-conjugated idiotype-specific antiserum, which recognizes the
J591-derived scFv. After washing and incubation with 10% normal
mouse serum, lymphocytes were stained with a PE-conjugated
anti-CD8 mAb. Y axis: CD8PE, X axis: Pz -1 signal. Left panel: Mock
transduction; right panel: Pz -1 transduction. The percentage of cells
present in each quadrant is indicated.
tients. We demonstrate that Pz-1 is capable of directing
( )peripheral blood lymphocytes PBL to specifically recog-
nize and lyse prostate cancer cells expressing PSMA. We
show that cytotoxicity against PSMA-positive target cells
was obtained in the PBL of 5 out of 5 patients. Furthermore,
we assessed the cytokine response of T cells transduced
with Pz-1 upon contact with PSMA-positive cells and exam-
ined whether CD28-mediated costimulation synergized
with Pz-1 signaling to augment the cytokine release of
PSMA-specific human T cells. These observations have
important implications for the generation and use of geneti-
cally engineered autologous lymphocytes to treat cancer.
Materials and Methods
Cell Lines
Retroviral producer cells were maintained in Dulbecco’s
( ) (modified Eagle’s medium DMEM Mediatech, Herndon,
) ( )VA supplemented with 10% fetal calf serum FCS as
[ ]described 9 . Prostate cancer cell lines, PC-3 and LNCaP,
and murine thymoma EL4 cells were maintained in RPMI
(with 10% FCS. NIH3T3 fibroblasts American Type Culture
)Collection, Rockville, MD were maintained in DMEM with
( )10% donor calf serum DCS, Hyclone, Logan, UT . All
( )media contained penicillin 100 U/mL and streptomycin
( )100 mg/mL .
PBL Collection and Transduction
PBL harvest and retroviral infection were carried out as
[ ]described elsewhere 9 . After retroviral infection, PBL were
(maintained in RPMI with 10% human serum Pel-Frez,
) (Brown Deer, WI and 20–50 IU/mL interleukin-2 IL-2,
)Chiron, Emeryville, CA .
Flow Cytometry
Pz-1 artificial T-cell receptor expression in PBL was eval-
uated by incubating the transduced lymphocytes with fluo-
( )rescein isothiocyanate FITC -conjugated idiotype-
specific antiserum, which recognizes the prostate-specific
( )membrane antigen PSMA –scFv. PSMA expression in tar-
[ ]get or feeder cells was determined with the J591 mAb 8 .
B7.1 expression in the feeder cells was determined with
( )mAb BB1 PharMingen, San Diego, CA , specific for human
B7.1.
PBL Cocultivation
For cocultivation with fibroblasts, 105 NIH3T3 cells per
well were irradiated and cultured in AIM-V serum free media
( )Gibco-BRL, Gaithersburg, MD supplemented with 5%
DCS. The following day, 106 T cells per well were added.
Supernatants were analyzed at 24, 48, and 72 hours after
( )start of the cocultivation for IL-2 and interferon IFN -g with
( )ELISA kits Genzyme, Cambridge, MA .
Cytotoxicity Assays
( )Cytotoxic T lymphocyte CTL assays were performed 4
to 14 days after PBL transduction. Transduced PBL were
( )incubated for 4 hours at different effector to target E:T
ratios with 104 chromium51–labeled target cells at 378.
Triplicate supernatants were counted using an automated
gamma counter. Percent specific 51Cr release was calcu-
(51 ) (lated by Cr releaseyspontaneous release / maximum
51 )Cr releaseyspontaneous release =100.
Results
Pz-1 Transduction and Expression in Human Primary T
Lymphocytes
The PSMA specific –z chain chimeric receptor Pz-1 was
( )cloned into a retroviral vector Figure 1A and transduced in
Table 1. Prostate Cancer Patient Demographics.
Current Time Since GG Stage at Treatment Current Stage Current PSA
U †( ) ( )Age Diagnosis mo Diagnosis ng/mL
Patient 1 67 19 3q 3 T1c Observation T1c 10
Patient 2 85 251 5q 4 T3 Hormonal T4Mq 501
Patient 3 54 8 4q 5 T1c RRP pT3CN0Mx 4
rising PSA
UTime elapsed between PBL harvest and date of diagnosis of prostate cancer.
† ( )Reference range of PSA, 0–4 ng/mL. Rising PSA is biochemical evidence of residual prostate cancer site of residual disease unknown .
( )GG: Gleason grade of most recent prostate cancer pathology; RRP: radical retropubic prostatectomy .
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Table 2. Gene Transduction Efficiency in T Cells from Prostate Cancer
Patients Measured on Day of CTL Assay.
Patient %TR %CD8 %CD56 %CD16
Pt 1 Pz-1 23 15 -1 -1
Pt 2 Pz-1 40 13 -1 -1
Pt 3 Pz-1 49 44 5 -1
Pt 1 NTP 18 15 ND ND
Pt 2 NTP 37 13 ND ND
Pt 3 NTP 27 44 ND ND
(%TR, percentage of gene transduction measured as shown in Figure
2B; %CD8, percentage of CD8q T cells, %CD56, percentage of CD56q
q )cells; %CD16, percentage of CD16 cells; ND, not done .
patient PBL with gibbon ape leukemia virus envelope–
[ ]pseudotyped virions as previously described 9 . PBL were
harvested from five prostate cancer patients in a variety of
clinical stages, including the three representative cases
shown in Table 1. Gene transfer efficiency, monitored by
(fluorescence-activated cell sorter FACS; Becton Dickinson
)& Co and analysis with a Pz-1 idiotype–specific antiserum
( ) qFigure 1B , varied between 20% and 50% in both CD8
q ( ) qand CD4 cells Table 2 . CD8 cells represented 13% to
44% of the different cultures, whereas cells expressing the
( )CD56 and CD16 markers found on natural killer NK cells
represented fewer than 1% of the cells in two cases and 5%
[ ]in the third. Gene transfer efficiency of the marker NTP 9 ,
a mutated human low-affinity nerve growth factor receptor
( )used as control Table 2 .
Pz-1 Directs PSMA-Specific Cytotoxicity in T Cells From
Prostate Cancer Patients
CTL assays were first performed on LNCaP, a human
prostate cancer cell line that abundantly expresses PSMA
[ ] ( )6,8 Figure 2A . As shown in Figure 2B, the PBL of all
three patients were able to recognize and lyse 51Cr–labeled
LNCaP after transduction with Pz-1 but not NTP. PC-3, a
human prostate cancer cell line normally negative for PSMA,
and EL-4, a murine thymoma, were transduced with a
(retrovirus encoding PSMA Latouche et al., unpublished
)observations . PSMA expression was confirmed by Western
Figure 2. Pz -1– transduced prostate cancer patient T lymphocytes lyse
( ) (LNCaP cells. A LNCaP cell expression of PSMA. FACS Becton
)Dickinson & Co analysis of wild type LNCaP cells. Cells were stained
with mAb J591 followed by FITC-conjugated goat anti -mouse
( ) ( )GAM-FITC antibody. Y axis: cell count, X axis: fluorescence 515 nm .
F ( )PSMA: PSMA signal, GAM : GAM-FITC antibody alone signal. B
Pz-1 directed cytotoxicity against LNCaP cells. PBL from three patients
( ) [ ]Tables 1 and 2 were transduced with either Pz -1 or NTP 9 . Trans-
duced PBL were used in CTL assays with LNCaP target cells. Percent-
age of specific lysis is represented on the Y axis, effector to target ratio
on the X axis.
( ) (blot analysis data not shown and by FACS Becton Dickin-
)son & Co analysis with different monoclonal antibodies
( )mAbs specific for PSMA. Figure 3A shows the FACS
( )Becton Dickinson & Co analysis of PSMA expression in
transduced PC-3 and EL-4 cells. Staining of the parental
PC-3 or EL-4 shows no detectable PSMA expression.
( q)Transduced PC-3 cells PSMA were of comparable
( )brightness to LNCaP cells Figure 2A .
T-cell populations transduced with Pz-1 but not NTP
lysed both human and murine PSMAq target cells very
( )effectively Figure 3B and C . The same results were
achieved with Pz-1–transduced PBL from two other patients
(with advanced, hormone-refractory prostate cancer data
)not shown . Cytotoxicity was PSMA-specific, as Pz-1–
transduced T cells did not kill PSMA-negative PC-3 or EL-4
cells any more than NTP-transduced lymphocytes. Back-
Figure 3. Pz -1– transduced prostate cancer patient T lymphocytes
( )specifically lyse target cells expressing PSMA. A Left panel: FACS
( ) ( -)Becton Dickinson & Co analysis of wild type PC-3 cells PSMA and
( q) - ( )PSMA-transduced PC-3 PSMA ; PSMA cells dotted line coincide
with PC-3 cells stained with the secondary GAM-FITC antibody alone
( ) [ ]data not shown . Cells were stained with mAb J591 8 , followed by
( )GAM-FITC antibody. Y axis: cell count; X axis: fluorescence 515 nm .
( )Right panel: FACS Becton Dickinson & Co analysis of wild type EL-4
( -)murine thymoma cells PSMA and PSMA-transduced EL-4 cells
( q) ( ) qPSMA . B Pz-1–transduced PBL specifically lyse PSMA target
( )cells. PBL from three patients Tables 1 and 2 were transduced with
[ ]either Pz -1 or NTP 9 . Percentage of specific lysis is represented on
the Y axis, effector to target ratio on the X axis. Targets are PC3-PSMAq
- ( ) ( ) ( )and PC3-PSMA wild type , as described in A, left panel . C Pz -1–
transduced PBL specifically lyse PSMAq EL-4 cells. Pz -1q–transduced
PBL of all patients effectively lysed PSMAq targets. Background activity
was variable on human target cells and uniformly low on murine target
cells.
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ground cytotoxicity levels varied on the human target cell
lines but remained very low on the murine cells, suggesting
that the allogeneic disparity between patient T cells and
human target cell lines accounted for the higher background
levels. The level of cytolytic activity did not closely correlate
with the transduction rate achieved or the percentage of
CD8q in each case. Thus, elevated PSMA-specific cytotoxi-
city was obtained in Pz-1–transduced T cells in five of five
prostate cancer patients, independent of their age and clini-
cal stage of disease.
Pz-1 Signaling Causes Cytokine Secretion by Transduced
PBL
To further assess the response of Pz-1–transduced pri-
mary T cells to PSMA, we investigated whether Pz-1q PBL
could release cytokines upon engagement with cell-bound
PSMA. We established a cocultivation system in which
transduced PBL are cultured on a monolayer of NIH3T3
fibroblasts engineered to express PSMA. NIH3T3 cells were
transduced with retrovirus encoding PSMA, human B7.1
( )CD80 , or both PSMA and B7.1. Figure 4A shows the
( )FACS Becton Dickinson & Co analysis of fibroblasts coex-
(pressing PSMA and B7.1 Latouche et al., unpublished
)observations . NIH3T3 cells expressing either PSMA or
B7.1 alone showed the same respective fluorescence pat-
( )tern data not shown . Control NIH3T3 cells stained with
( ) ( )either mAbs J591 anti-PSMA or BB1 anti-B7.1 were
F ( )negative, coinciding with the GAM peak data not shown .
T cells were cocultured in the absence of exogenous IL-2.
Culture supernatants were sampled after 24, 48, and 72
hours and assayed for IL-2 and IFN-g secretion. Pz-1–
transduced T cells released significant amounts of IL-2
( ) ( )Figure 4B and IFN-g data not shown 24 hours after
exposure to PSMAq feeder cells. IL-2 was barely de-
tectable in the supernatant of Pz-1q T cells cocultured with
NIH3T3 cells expressing B7.1 alone or in the absence of
Figure 4. NIH3T3 fibroblast feeder cells coexpressing PSMA and B7.1
( ) ( )CD80 direct cytokine release by Pz -1–transduced T cells. A Trans-
duced NIH3T3 feeder cells were stained with mAb J591 as described in
Figure 2 or with FITC– labeled mAb BB1 specific for B7.1. Y axis: cell
count; X axis: PSMA or B7.1 signal. GAM F: GAM-FITC antibody alone.
( )PSMA and B7.1 indicate the fluorescence obtained for each stain. B
PSMA induced IL- 2 secretion by Pz -1q T cells. Pz -1–transduced T
cells were cocultured with NIH3T3 fibroblast feeder cells. Supernatants
collected 24, 48, and 72 hours after the start of the coculture were
assayed for IL- 2 by ELISA. B7q PSMA, PSMA, B7 refer to the
molecules expressed by the different fibroblast monolayers. Results are
from quadruplicate experiments. Error bars represent 2 standard devia-
tions.
( )any feeder layer. However, IL-2 and IFN-g data not shown
secretion were strongly potentiated in the presence of both
PSMA and B7.1, resulting in 10–fold higher IL-2 release
( )after 24 hours Figure 4B . Thus, cytokine secretion con-
firmed that B7.1-mediated signaling provided functional cos-
timulation in Pz-1 – transduced T cells stimulated by
cell-bound antigen, suggesting that Pz-1 signaling syner-
gized with B7.1–mediated costimulation. During the coculti-
vation, Pz-1q PBL destroyed PSMAq monolayers within 48
hours, whereas the PSMA- B7.1q monolayer remained in-
tact during the entire 4-day cocultivation.
Discussion
Our results have several implications for the generation,
expansion, and therapeutic use of T lymphocytes geneti-
cally targeted to a defined antigen. Using highly efficient
[ ]retroviral-mediated gene transfer 9 , we were able to inves-
tigate Pz-1 function in human primary CD4q and CD8q T
cells.
First, we show that T cells of cancer patients can be
genetically directed to recognize and lyse tumor cells that
express the cell-surface antigen PSMA. The demonstration
that an antigen-specific z chain fusion receptor is functional
in cancer patient lymphocytes is an important step toward
the implementation of adoptive cell therapies based on the
genetic alteration of autologous polyclonal PBL. Indeed,
defective TCR signaling has been observed in chronic tu-
[ ]mor bearing mice and cancer patients 10,11 . However, we
found that the Pz-1 receptor was functional in T cells in five
of five cancer patients, including three with advanced dis-
ease. These results suggest that T cell activation defects
are either uncommon or bypassed by genetically modifying
T cells with z chain fusion receptors. These results, there-
fore, alleviate our earlier concerns that findings in normal T
cells might not extend to cancer patient cells.
All reports to date describing z chain fusions have fo-
cused on the antigen-specific killing imparted by the recep-
( [ ])tor reviewed in Ref. 4 . However, the ability of z chain
receptors to provide antigen specific helper functions has
not been examined. We show that Pz-1 specifically elicited
cytokine release when culturing the transduced lympho-
cytes on PSMAq murine fibroblasts. This result indicates
that the Pz-1 receptor provided a sufficient signal to trigger
T-cell activation. However, the cytokine secretion was rela-
( )tively weak and not sustained Figure 4B . We therefore
investigated whether providing costimulation to the trans-
duced lymphocytes would increase their cytokine response.
Indeed, whereas z chain signaling provides a powerful acti-
vation signal after engagement of the physiologic TCR, full
T-cell activation typically requires a costimulatory signal
[ ]12 . Costimulation could act by amplifying the activation
signal or offsetting putative proapoptotic signaling by the
Pz-1 receptor.
On a practical level, our results also suggest a strategy to
expand cells expressing an artificial TCR. In vitro, fibroblast
monolayers that express antigen and B7 are very effective
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as shown here. Different approaches can be envisaged to
provide costimulation in vivo. One is to express B7.1 in
[ ]tumor cells 13 , providing that B7.1 can be expressed in a
sufficient fraction of the tumor cells. Another is to provide
[ ]antigen-dependent costimulation 5 by expressing in the T
cells an antigen-specific CD28 fusion receptor. In this man-
ner, contact with PSMAq cells would provide CD28 signal-
ing in the absence of the B7.1 or B7.2 ligands on tumor
cells. Dendritic cells, which constitutively express B7.1, do
not express native PSMA and thus could not appropriately
stimulate the transduced T cells. To do so, the dendritic
cells would have to be genetically engineered to express
[ ]the intact cell-surface molecule 14 .
Retroviral-mediated gene transfer is efficient in both
q q (CD4 and CD8 subsets of human T lymphocytes Ref.
[ ] )9 ; Figure 1B . As the Pz-1 receptor signals for both the
( )activation of cytolysis Figures 2 and 3 and cytokine secre-
( )tion Figure 4B , it becomes envisagable to combine the
adoptive transfer of PSMA-targeted CD4q and CD8q T
cells. Cytokine release by the former should sustain the
activity of the latter, in addition to exerting either proinflam-
matory and/or antitumoral functions. The expression of an
artificial T-cell receptor that is not restricted by either MHC
class I or class II creates the intriguing situation in which
both CD4q and CD8q T lymphocytes could be activated
side by side at the tumor site.
PSMA is expressed by normal prostate epithelial cells,
and its expression is increased in prostate cancer, including
metastatic and hormone-deprived cells. It is also expressed
on the neovasculature of multiple carcinomas, the brush
([ ]border of duodenal epithelium and salivary glands 6–8
)Chang et al., manuscript submitted . Thus, Pz-1 may be
useful to target T cells to local and metastatic prostate
cancer and tumor neovasculature of other solid tumors.
Expression on normal tissues does not necessarily repre-
sent an obstacle to the therapeutic use of monoclonal
[ ]antibodies 15,16 . Clinical studies are underway to define
the biodistribution of the PSMA-specific J591 antibody in
vivo.
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